Only a few days to go: We’re raising £25,000 to keep TheyWorkForYou running and make sure people across the UK can hold their elected representatives to account.

Donate to our crowdfunder

Mental Health

Health written question – answered on 10th January 2008.

Alert me about debates like this

Photo of Mark Harper Mark Harper Shadow Minister (Work and Pensions)

To ask the Secretary of State for Health pursuant to the answer of 5 December 2007, Official Report, column 1318W, on mental health and employment: meeting the challenge, how much of the £173 million will be spent in each year to 2010-12.

Photo of Ivan Lewis Ivan Lewis Parliamentary Under-Secretary (Department of Health) (Care Services)

The comprehensive spending review (CSR) covers the period to 2010-11. Additional investment in the Improving Access to Psychological Therapies programme, identified in the CSR 2007-10 will be in excess of £300 million, with an investment of £33 million in 2008-09, £103 million in 2009-10, rising to £173 million by 2010-11.

Does this answer the above question?

Yes1 person thinks so

No1 person thinks not

Would you like to ask a question like this yourself? Use our Freedom of Information site.


Dee Speers
Posted on 13 Jan 2008 12:16 am (Report this annotation)

How many Mental health Trusts and PCT's have dual diagnosis and integreated services available at the point of contact? This early identification of possible mental health problems being self medicated by use of drugs and /or alcohol problems may improve actual access to available psychological therapies programme, which it seems despite the identified funding are still in short supply. Spending within the mental health service must be ring-fenced to protect it from being "clawed back" at the end of the financial year.If not we risk the same thing happening as in identified drug resaerch monies which were effectively redistributed after agreement to spend on drug research but failed to do so and the resultant problems associated with cannabis and mental health problems can be attributed to this and the Governments reclassification of the drug.